Robert Holmes, DO
Rheumatology · Pollocksville, NCNPI 1053496349
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $157,194 of the $214,822 with a category attached, or 73.2%. 31 manufacturers reported payments, led by AbbVie at 35.4% of the total. Reporting peaked in 2019 at $63,201 and has fallen 58.0% since, to $26,519 in 2025. Among rheumatology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,366 payments — averaging $157.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$76K
- Amgen$38K
- Regeneron Healthcare Solutions, Inc.$32K
- Mallinckrodt Hospital Products Inc.$32K
- Bristol Myers Squibb$22K
- Sanofi$3K
- plus $11K from 25 others
What the payments were for
- Consulting fees$10,9635%
- Speaking & faculty fees$157,19473%
- Travel & lodging$24,43311%
- Food & beverage$22,06810%
- Education$1640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 212 | $76,011 |
| Amgen(2 entities) | 279 | $38,303 |
| Regeneron Healthcare Solutions, Inc. | 53 | $32,143 |
| Mallinckrodt Hospital Products Inc. | 66 | $32,125 |
| Bristol Myers Squibb | 31 | $22,498 |
| Sanofi | 8 | $2,943 |
| Novartis | 94 | $1,678 |
| Pfizer | 166 | $1,536 |
| Lilly USA, LLC | 92 | $1,447 |
| UCB, Inc. | 65 | $1,112 |
| GSK | 63 | $908 |
| Johnson & Johnson | 30 | $756 |
| AstraZeneca | 43 | $745 |
| Aurinia Pharma U.S., Inc. | 51 | $702 |
| Radius Health, Inc. | 24 | $451 |
| Boehringer Ingelheim | 21 | $366 |
| E.r. Squibb & Sons, L.L.C. | 17 | $299 |
| Genentech USA, Inc. | 11 | $164 |
| Bayer | 17 | $150 |
| ANI Pharmaceuticals, Inc. | 6 | $140 |
| Fresenius Kabi USA, LLC | 5 | $122 |
| Octapharma USA, Inc. | 2 | $42 |
| Abbott | 2 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $21 |
| Edwards Lifesciences | 1 | $20 |
| Pharming Healthcare, Inc. | 1 | $19 |
| Medtronic | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$214,822 in reported general payments places this provider in the 95th percentile of 210 rheumatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 318 | $2,154,412 |
| ActharCorticotropin | 21 | $1,763,462 |
| Skyrizi PenRisankizumab-Rzaa | 46 | $1,016,152 |
| Humira(Cf) PenAdalimumab | 96 | $754,690 |
| Orencia ClickjectAbatacept | 118 | $741,669 |
| Cosentyx Sensoready PenSecukinumab | 53 | $574,237 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 63 | $562,118 |
| KevzaraSarilumab | 105 | $454,874 |
| Actemra ActpenTocilizumab | 53 | $271,511 |
| Enbrel SureclickEtanercept | 36 | $269,137 |
| Xeljanz XrTofacitinib Citrate | 46 | $261,602 |
| Taltz AutoinjectorIxekizumab | 26 | $185,819 |
| Cosentyx Unoready PenSecukinumab | 19 | $171,137 |
| OtezlaApremilast | 32 | $164,043 |
| BenlystaBelimumab | 32 | $153,617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Linzess | $76,011 | $2,171,105336 claims |
| Mallinckrodt Hospital Products Inc.Acthar | $32,125 | $1,763,46221 claims |
| SanofiKevzara | $2,943 | $454,874105 claims |
| AmgenOtezla, Enbrel | $38,303 | $259,21345 claims |
| GSKBenlysta, Trelegy Ellipta | $908 | $160,53143 claims |
| NovartisCosentyx (2 Syringes) | $1,678 | $95,24713 claims |
| Lilly USA, LLCOlumiant, Trulicity | $1,447 | $93,24843 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $299 | $87,00512 claims |
| PfizerEliquis | $1,536 | $12,12817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 210 rheumatology providers in North Carolina.
Other rheumatology in Pollocksville
- Gordon LamCharlotte$2.7M
- Ralph SnydermanDurham$1.3M
- Wendy SimmonsWilmington$462K
- Andrew LasterCharlotte$421K
- Ana RossRaleigh$417K
- Gwenesta MeltonFayetteville$410K
- Joseph ShanahanDurham$407K
- Jill ZouzoulasCharlotte$377K
- Jill VargoAsheville$245K
- Kristin GowinAsheville$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.